Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGLEC7 | Q9Y286 | 6/20 | 0.51 |
| ▸ | LGALS8 | O00214 | 1/20 | 0.43 |
| ▸ | LGALS3 | P17931 | 1/20 | 0.43 |
| ▸ | LGALS4 | P56470 | 1/20 | 0.43 |
| ▸ | SELL | P14151 | 2/20 | 0.42 |
| ▸ | MAG | P20916 | 6/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | SELP | P16109 | 1/20 | 0.38 |
| ▸ | CD22 | P20273 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19490292 | 0.88 | SIGLEC7 (0.65) | SIGLEC7SELLMAGSELPCD22 | |
| SCHEMBL21064182 | 0.86 | SIGLEC7 (0.53) | SIGLEC7LGALS8LGALS3LGALS4SELL | |
| SCHEMBL17573060 | 0.80 | SIGLEC7 (0.50) | SIGLEC7LGALS8LGALS3LGALS4SELL | |
| SCHEMBL17572912 | 0.80 | SIGLEC7 (0.50) | SIGLEC7LGALS8LGALS3LGALS4SELL | |
| SCHEMBL19490291 | 0.79 | SIGLEC7 (0.61) | SIGLEC7SELLMAGSELPCD22 | |
| SCHEMBL17571031 | 0.79 | SIGLEC7 (0.61) | SIGLEC7SELLMAGSELPCD22 | |
| SCHEMBL17571017 | 0.79 | SIGLEC7 (0.61) | SIGLEC7SELLMAGSELPCD22 | |
| SCHEMBL17571032 | 0.77 | SIGLEC7 (0.47) | SIGLEC7LGALS8LGALS3LGALS4SELL | |
| SCHEMBL17572911 | 0.77 | SIGLEC7 (0.52) | SIGLEC7LGALS8LGALS3LGALS4SELL | |
| SCHEMBL21064188 | 0.75 | LGALS3 (0.49) | SIGLEC7LGALS8LGALS3LGALS4SELL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10307471-B2 | Immunity inducer for saccharide antigens | NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY (JP) | 2019-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10307471-B2 | Immunity inducer for saccharide antigens | CD14, CD4, CD69 | SIGLEC7 4/4885LGALS8 193/4885LGALS3 248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.